文献速递眼底病与葡萄膜炎

抗高温需求A1(HtrA1)Fab抗体Galegenimab(FHTR2163)治疗年龄相关性黄斑变性继发地图样萎缩的2期研究

Phase 2 Study of the Anti-High Temperature Requirement A1 (HtrA1) Fab Galegenimab (FHTR2163) in Geographic Atrophy Secondary to Age-Related Macular Degeneration.
PubMed 文献 · Am J Ophthalmol · 2025-03-13

这项2期、单盲、随机临床试验纳入337例年龄相关性黄斑变性继发地图样萎缩患者,随机接受Galegenimab 20 mg每4周、每8周或假注射。第72周GA面积平均变化在治疗组与假注射组间无统计学显著差异,但治疗组眼内炎症发生率为7.1%(16/224),数据监测委员会基于早期获益/风险分析建议提前终止研究。

要点

  • Galegenimab 20 mg每4周或每8周与假注射相比,第72周GA面积平均变化无统计学显著差异。
  • 治疗组眼内炎症发生率为7.1%(16/224例),数据监测委员会建议提前终止研究。
  • 抑制HtrA1的Fab抗体未能减缓地图样萎缩进展。

核心结论

  • Galegenimab给药与假注射相比,第72周GA面积较基线的平均变化未显示差异。
  • 用Fab抑制HtrA1未能减缓GA进展。

研究设计与样本

  • 2期、单盲、随机临床试验。
  • 纳入研究眼最佳矫正视力字母评分≥24个字母且基线GA病灶大小2.54~25.4 mm²的GA患者。
  • 患者按2:1:2随机接受Galegenimab 20 mg每4周、每8周或假注射每4/8周。
  • 主要终点为基线与第72周之间经眼底自发荧光测量的GA面积平均变化。
  • 数据监测委员会对正在进行研究的累积安全性/有限疗效数据进行定期非盲审查。

主要发现

  • 337例接受至少1次给药且至少有一次基线后GA面积测量的患者中,第72周GA面积较基线校正平均变化在Galegenimab每4周组为2.67 mm²、每8周组为2.50 mm²、合并假注射组为2.38 mm²。
  • 治疗组与假注射组之间的差异无统计学意义。
  • 治疗组患者眼内炎症发生率为7.1%(16/224例)。
  • 数据监测委员会基于早期获益/风险分析建议提前终止研究。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 数据监测委员会基于早期获益/风险分析建议提前终止研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate the safety, tolerability, and efficacy of intravitreal injection of galegenimab, an anti-HtrA1 FAb, in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). DESIGN: Phase 2, single-masked, randomized clinical trial. METHODS: Eligible GA patients with BCVA letter scores of ≥ 24 letters and baseline GA lesion size 2.54∼25.4 mm2 in the study eye were enrolled. Patients were randomized 2:1:2 to receive 20 mg galegenimab every 4 (Q4W) or 8 weeks (Q8W), or sham Q4/8 W. The primary endpoint was mean change in GA area from baseline to Week 72 measured by fundus autofluorescence. A data monitoring committee (DMC) conducted periodic unmasked review of cumulative safety/limited efficacy data of the ongoing study. RESULTS: Among 337 patients who received ≥ 1 dose and have at least one postbaseline GA area measurement, the adjusted mean change in GA area from baseline to Week 72 was 2.67, 2.50, and 2.38 mm2 for the galegenimab Q4W, galegenimab Q8W, and pooled sham arms, respectively. Differences between the treated and sham groups were not statistically significant. However, the rate of intraocular inflammation was high (7.1%, 16/224 patients) among treated patients. The DMC recommended early termination of the study based on an early benefit/risk analysis. CONCLUSION: Galegenimab administration did not show a difference in mean change in GA area from baseline to Week 72 compared with sham. Inhibition of HtrA1 with a Fab did not slow down GA progression.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Eichenbaum DA, Holekamp N, Khanani AM, et al. Phase 2 Study of the Anti-High Temperature Requirement A1 (HtrA1) Fab Galegenimab (FHTR2163) in Geographic Atrophy Secondary to Age-Related Macular Degeneration. Am J Ophthalmol. 2025. PMID: 40089174. doi:10.1016/j.ajo.2025.03.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。